RevBio Gets FDA OK to Expand TETRANITE Bone Adhesive Trial, Earns CMS Coverage

RevBio has received U.S. Food and Drug Administration (FDA) approval to expand its ongoing clinical trial to immediately fixate cranial flaps using TETRANITE, the company’s bone adhesive biomaterial. The company also received reimbursement coverage from the Centers for Medicare and Medicaid (CMS) for use of TETRANITE to replace metal plates and screws.

RevBio had previously received FDA approval to begin a first-in-human clinical study for an initial five patients to restore cranial flaps after craniotomy procedures and repair extradural use cases where intentional durotomies aren’t required. Approval of the trial expansion was based on successful demonstration of safety in the first five patients treated with TETRANITE.

The neurosurgeon investigators in this study can now use TETRANITE in intradural use cases, such as tumor resection surgeries and other cranial procedures, which require intentional durotomies.

“Metal plates and screws can produce radiographic artifacts which make it difficult to accurately interpret patient imaging following surgery. Furthermore, traditional cranial flap closure methods do not lead to the full osseous reintegration of the flap with the skull, resulting in issues with flap movement, patient pain, and the potential for post-surgical infection. Because TETRANITE eliminates radiographic artifacts and results in osseous union of bone flaps with the surrounding skull, it could become the new standard of care for cranial surgeries,” said Kevin T. Foley, MD, professor in the Departments of Neurosurgery and Orthopedic Surgery & Biomedical Engineering at the University of Tennessee Health Science Center in Memphis, Tennessee, Chairman of Semmes-Murphey Clinic, and Chairman of the Board and Medical Director for the Medical Education & Research Institute (MERI).

Dr. Foley also serves as a member of the board and chief medical officer for RevBio.

Private insurance companies will also typically provide reimbursement for CMS approved products. As a result, RevBio can now charge hospitals for this product.

“We are pleased to receive reimbursement approval from CMS during our IDE clinical trial,” said Grayson Allen, CFO/COO of RevBio. “This will enable RevBio to establish a price with healthcare providers, which is a very important step in the overall product commercialization process.”